Parisi, Giulia
Saco, Justin D.
Salazar, Felix B.
Tsoi, Jennifer
Krystofinski, Paige
Puig-Saus, Cristina
Zhang, Ruixue
Zhou, Jing
Cheung-Lau, Gardenia C.
Garcia, Alejandro J.
Grasso, Catherine S.
Tavaré, Richard
Hu-Lieskovan, Siwen
Mackay, Sean
Zalevsky, Jonathan
Bernatchez, Chantale
Diab, Adi
Wu, Anna M. http://orcid.org/0000-0001-8487-823X
Comin-Anduix, Begoña
Charych, Deborah
Ribas, Antoni http://orcid.org/0000-0003-3669-8458
Funding for this research was provided by:
Foundation for the National Institutes of Health (R35 CA197633)
Article History
Received: 28 June 2019
Accepted: 3 October 2019
First Online: 31 January 2020
Competing interests
: A.R. has received honoraria from consulting with Amgen, Bristol-Myers Squibb, Chugai, Genentech, Merck, Novartis and Roche, is or has been a member of the scientific advisory board and holds stock in Advaxis, Arcus Biosciences, Bioncotech Therapeutics, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Kite-Gilead, Lutris Pharma, Merus, PACT Pharma, Rgenix and Tango Therapeutics. J. Zhou and S.M. are employees of Isoplexis. R.T. is an employee of Regeneron. J. Zalevsky and D.C. were employees of Nektar Therapeutics during the conduct of this research and hold stock. A.M.W. holds stock and is a consultant to ImaginAb. The remaining authors declare no competing interests.